Meeting
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
BrUOG 324: Adjuvant nivolumab and low-dose ipilimumab for stage IIC, III, and resected stage IV melanoma: A phase II Brown University Oncology Research Group trial.
Authors
Maria Constantinou
Rhode Island Hosp Brown Univ, East Greenwich, RI
Maria Constantinou, Michael P. Vezeridis, Martin A. Weinstock, Joanna Walker, Thomas J. Miner, Peter Barth, Kayla Rosati, Kristen Mitchell, Sopha Dionson, Wendy Turchetti, John Vatkevich, William Matthew Rafelson, Kalyan C. Mantripragada, Howard Safran
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A
Track
Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses
Sub Track
Immune Checkpoints and Stimulatory Receptors
Clinical Trial Registration Number
NCT02656
Citation
J Clin Oncol 36, 2018 (suppl 5S; abstr TPS202)
DOI
10.1200/JCO.2018.36.5_suppl.TPS202
Abstract #
TPS202
Poster Bd #
N6
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study to evaluate the safety and efficacy of IMM-101 in combination with checkpoint inhibitors in patients with advanced melanoma: Final results of the IMM-101-015 trial.
First Author: Alberto Fusi
Poster
2023 ASCO Annual Meeting
A randomized phase 2 trial of encorafenib + binimetinib + nivolumab vs ipilimumab + nivolumab in BRAFV600-mutant melanoma brain metastases: SWOG S2000.
First Author: Zeynep Eroglu
Poster
2023 ASCO Genitourinary Cancers Symposium
A phase II study of nivolumab with ipilimumab and cabozantinib in patients with untreated renal cell carcinoma brain metastases.
First Author: Jianbo Wang
Poster
2022 ASCO Annual Meeting
The NADINA trial: A multicenter, randomised, phase 3 trial comparing the efficacy of neoadjuvant ipilimumab plus nivolumab with standard adjuvant nivolumab in macroscopic resectable stage III melanoma.
First Author: Minke W. Lucas